Moors & Cabot Inc. Has $2.20 Million Stake in Boston Scientific Co. (NYSE:BSX)

Moors & Cabot Inc. lowered its stake in shares of Boston Scientific Co. (NYSE:BSX) by 1.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,245 shares of the medical equipment provider’s stock after selling 298 shares during the quarter. Moors & Cabot Inc.’s holdings in Boston Scientific were worth $2,199,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Triad Wealth Partners LLC acquired a new position in shares of Boston Scientific during the second quarter worth approximately $26,000. Values First Advisors Inc. acquired a new position in Boston Scientific during the third quarter worth $28,000. E Fund Management Hong Kong Co. Ltd. acquired a new position in Boston Scientific during the third quarter worth $30,000. Capital Performance Advisors LLP acquired a new position in Boston Scientific during the third quarter worth $30,000. Finally, Andra AP fonden acquired a new position in Boston Scientific during the second quarter worth $29,000. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on BSX shares. Bank of America increased their price objective on Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. Royal Bank of Canada increased their target price on Boston Scientific from $95.00 to $98.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Barclays raised their price target on Boston Scientific from $78.00 to $86.00 and gave the company an “overweight” rating in a report on Thursday, August 22nd. Canaccord Genuity Group raised their target price on Boston Scientific from $88.00 to $98.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Robert W. Baird raised their target price on Boston Scientific from $90.00 to $91.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $93.39.

Boston Scientific Stock Down 0.2 %

BSX stock opened at $90.17 on Thursday. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The business has a 50 day moving average price of $85.71 and a two-hundred day moving average price of $79.92. The company has a market cap of $132.90 billion, a price-to-earnings ratio of 74.52, a P/E/G ratio of 2.56 and a beta of 0.79. Boston Scientific Co. has a twelve month low of $53.93 and a twelve month high of $91.08.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The firm had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same period last year, the company earned $0.50 earnings per share. The business’s revenue was up 19.3% compared to the same quarter last year. Analysts anticipate that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 162,777 shares of Boston Scientific stock in a transaction on Monday, October 7th. The stock was sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the transaction, the chief executive officer now directly owns 1,572,096 shares of the company’s stock, valued at $133,046,484.48. The trade was a 9.38 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total value of $585,594.38. Following the completion of the transaction, the executive vice president now directly owns 34,748 shares of the company’s stock, valued at $2,913,967.28. This represents a 16.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 309,270 shares of company stock worth $26,196,718 in the last ninety days. 0.50% of the stock is owned by company insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.